News & stories

News | Apr 23, 2024

As Danaher reports earnings, MSF repeats call for $5 GeneXpert tests

Medical testing shouldn't be a luxury. Danaher and Cepheid must drop the price of GeneXpert for low- and middle-income countries

News | Sep 29, 2023

Failure to reauthorize global AIDS program would be catastrophic

MSF urges US lawmakers to sustain lifesaving support for PEPFAR

News | Sep 20, 2023

UN pandemic preparedness declaration doesn't do enough

Leaders have a responsibility to ensure health emergency responses take affected people’s needs into consideration.

News | Aug 17, 2023

MSF refuses to sign ViiV NDA for access to lifesaving HIV drug

Signing confidentiality clauses on supply and pricing undermines transparency, accountability, and access to the medicine.

News | May 26, 2023

MSF welcomes World Health Assembly resolution on disease testing

Governments must now implement the resolution and make sure diagnostic tools are widely affordable and accessible

News | May 11, 2023

MSF: Access to HIV tests uncertain as companies stop production

MSF calls on Abbott and BD to ensure adequate supply of CD4 tests and equipment

News | May 03, 2023

Gilead must do more to make lifesaving HIV drug widely available

It's time for Gilead to prioritize broad access to L-AmB across low- and middle-income countries.

News | Mar 30, 2023

ViiV must improve failing access strategy for lifesaving HIV drug

ViiV must do more to ensure people in low- and middle-income countries, including MSF patients, have access to injectable PrEP as generic versions are likely years away

News | Nov 29, 2022

MSF: ViiV must make groundbreaking HIV prevention injection affordable and available

Removing barriers that block access to this medicine could help avoid millions of new HIV infections.

News | Sep 19, 2022

MSF: Donor countries must increase funding pledges during Global Fund replenishment conference